Technology Clinic Outcome Reporting System Research Articles

Association of endometrial thickness with live birth rate: a study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System.

Association of endometrial thickness with live birth rate: a study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System.

Outcomes of in vitro fertilization cycles with embryo donation compared to double gamete donation with cryopreserved donor oocytes.

Outcomes of in vitro fertilization cycles with embryo donation compared to double gamete donation with cryopreserved donor oocytes.

O-308 Characterizing the association between in vitro fertilization and VACTERL: a population-based assessment in 1.3 million live births

Abstract Study question Is conception using in vitro fertilization (IVF) associated with the multiple congenital anomaly pattern referred to as VACTERL? Summary answer Children conceived through IVF were more than twice as likely to develop VACTERL compared to those naturally conceived (OR 2.57, 95% CI 1.93-3.39). What is known already VACTERL (vertebral defects, anal atresia, cardiac defects, tracheo-esophageal fistula, renal anomalies, and limb abnormalities) is a multiple congenital anomaly pattern with a likely multifactorial origin, as few genetic or non-genetic risk factors have been identified. Some studies have suggested a potential link between IVF and VACTERL, yet this relationship has not been thoroughly investigated while accounting for other maternal characteristics. Given the rarity of VACTERL, large datasets with comprehensive information on fertility treatment parameters, maternal characteristics, and birth outcomes are essential to better understand this association. Study design, size, duration We performed a population-based study of live births in four U.S. states (Massachusetts, New York, North Carolina, and Texas) between 2004 and 2018, linking birth records and birth defect data to IVF cycles reported in the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS). Naturally conceived births were selected as controls at a 10:1 ratio during the same period as the IVF birth. The study included a total of 1,315,867 live births. Participants/materials, setting, methods All study children were linked to state birth defect registries, with defects classified using British Pediatric Association codes. VACTERL cases were identified by code 759.890 or the presence of at least three associated anomalies. Children with known chromosomal or other genetic syndromes were excluded. Logistic regression was used to assess the association between IVF conception and VACTERL. Covariates included maternal age, race/ethnicity, education, and state. Main results and the role of chance We identified 363 cases of VACTERL - 78 conceived through IVF (0.053%) and 285 naturally conceived (0.024%). Of these, 232 cases were identified using the diagnostic code 759.890, while 131 additional cases were identified by at least three of the six VACTERL associated anomalies. The most frequent VACTERL congenital anomalies were cardiac defects (54%), followed by renal anomalies (50%) and anal atresia (32%). In unadjusted analysis, IVF was significantly associated with an increased prevalence of VACTERL (OR 2.27, 95% CI 1.75-2.89). After adjusting for maternal socio-demographics, the association was further strengthened (OR 2.57, 95% CI 1.93-3.39) and supported in sensitivity analyses restricted to 1,226,080 singletons (OR 2.74, 95% CI 1.92-3.83). Evaluation of specific IVF treatment parameters (n = 141,882) revealed the highest prevalence of VACTERL in 58 of 102,099 births from fresh embryos (0.057% vs. 0.050% from thawed embryos), 41 of 69,765 births from ICSI (0.059% vs. 0.052% without ICSI), and 27 of 48,629 births from male infertility (0.056% vs. 0.055% without male infertility). Refining our multivariable model of IVF, we found that use of ICSI without a diagnosis of male infertility had the strongest association with VACTERL of all IVF groups (OR 3.04, 95% CI 1.90-4.65) compared to natural conceptions. Limitations, reasons for caution We were unable to assess familial clustering and terminations in the prevalence of VACTERL. However, our analyses are representative of live births and we accounted for maternal characteristics associated with both birth defect risks and the use of fertility treatment. Wider implications of the findings The use of IVF is associated with VACTERL in offspring, but the absolute risk for VACTERL in IVF-conceived offspring remains low. The mechanisms underlying this association are unclear, but altered DNA methylation patterns have been implicated in both IVF and VACTERL etiology. Trial registration number No

O-307 The risk of birth defects identified during the first year of life is not associated with embryo stage at transfer among IVF-conceived children

Abstract Study question Is there an association between embryo stage at transfer and the risk of major birth defects in IVF conceptions? Summary answer There is no association between the embryo stage at fresh transfer and the risk of major birth defects in IVF conceptions. What is known already Extended blastocyst culture may be associated with differences in embryo gene expression and epigenetic modifications; there may also be an increased risk of adverse in neonatal outcomes associated with blastocyst culture. These differences may differentially affect the already increased risk of nonchromosomal birth defects in IVF-conceived offspring. Study design, size, duration This is a population-based cohort study linking IVF cycles reported to the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System (SART CORS) and United States vital statistics and birth defect registries. Live births from pregnancies reported from January 1, 2004 to December 31, 2017 from Massachusetts, North Carolina, Texas, and New York were analyzed. Participants/materials, setting, methods Logistic regression was used to estimate adjusted odds ratios (AORs) and 95% confidence intervals (CIs) of the risks of major chromosomal and nonchromosomal birth defects in singleton and twin live births (separately) associated with embryo stage at the time of fresh transfer. Models were adjusted for parental ages, maternal race and ethnicity, education, body mass index (BMI), fertilization method, pregestational/gestational diabetes and hypertension, infant sex, State, and year of birth and accounted for cycle clustering. Main results and the role of chance The study included 69,493 singleton live births (22,801 children from cleavage stage (day 2-3) fresh embryo transfers and 46,692 children from blastocyst stage (day 5-6) fresh embryos). The birth prevalence of major chromosomal defects was 22.8/10,000 in the cleavage group and 16.1/10,000 in the blastocyst group. The birth prevalence of nonchromosomal defects was 213.1/10,000 in the cleavage stage and 224.2/10,000 children in the blastocyst group. There was no difference in the risk of major chromosomal birth defects between children conceived from blastocyst compared to cleavage stage embryos in models adjusted for the above covariates (AOR 0.65, 95% CI 0.41 to 1.03). Similarly, there was no difference in the risk of nonchromosomal birth defects (AOR 1.03, 95% CI 0.90 to 1.19). In addition, 38,590 children born from twin conceptions were analyzed - 10,353 children that resulted from cleavage stage fresh embryos transfers and 28,237 children from blastocyst fresh embryo transfers. In adjusted logistic regression models there was no difference in risk of major chromosomal birth defects (AOR 0.82, 95% CI 0.46 to 1.45) in blastocyst-conceived twin children compared to cleavage-staged. Similarly, there was no difference in the risk of nonchromosomal birth defects (AOR 1.03, 95% CI 0.88 to 1.22). Limitations, reasons for caution Frozen embryo transfers were unable to be studied due to small sample sizes of cleavage stage thawed and transferred embryos. Data on birth defects were not available for miscarriages, terminations, or stillbirths, only for live births. Wider implications of the findings Culture to blastocyst with elective single embryo transfer is supported by ESHRE and ASRM to minimize multiple gestation. This work supports blastocyst transfer as safe for offspring with no association between the embryo stage at fresh transfer and the risk of major birth defects in IVF conceptions. Trial registration number No

United States racial/ethnic disparities in PGT-A use: an analysis of 2014–2020 SART CORS database

BackgroundThe use of preimplantation genetic testing for aneuploidy (PGT-A) allows for the selection of euploid embryos and has been thought to improve outcomes in ART, particularly in women ≥ 35 years old. However, little is known regarding PGT-A utilization among minority women in the United States (US). The objective of this study was to determine the trend of utilization of PGT-A in the US among minority women.MethodsWe conducted a retrospective cohort study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) database. We included initial autologous ART cycles performed between 2014 and 2020. We assessed the rate of PGT-A utilization by race/ethnicity.ResultsThis study included 150,604 PGT-A and 287,979 non-PGT-A initial autologous cycles. The overall trend of PGT-A utilization, regardless of race/ethnicity, increased from 11.5 to 49.0% (p < 0.001) over seven years. Of all ART cycles, 33% of White women used PGT-A, in comparison to 24% of Black women, 31% of Hispanic women, and 44% of Asian women (p < 0.001). Multiple Logistic Regression (MLR) determined race/ethnicity as an independent predictor of PGT-A utilization when adjusting for age, BMI, and AMH (p < 0.001). Compared to White women, MLR showed that Black and Hispanic women were 35% and 16% less likely to use PGT-A (aOR = 0.65, 95% CI 0.63–0.67, and aOR = 0.86, 95% CI 0.84–0.88, respectively, p < 0.001). In contrast, Asian women were 41% (aOR = 1.41, 95% CI 1.39–1.44) more likely to use PGT-A (p < 0.001). Overall, regardless of race/ethnicity, women 35 and older were 71% (aOR = 1.71, 95% CI 1.69–1.74) more likely to use PGT-A compared to women younger than 35 (p < 0.001).ConclusionDespite a significant increase in overall PGT-A utilization in the US over 7 years, utilization has been consistently less in ART cycles for Black and Hispanic women, in comparison to White women. This is in marked contrast to an increase in PGT-A utilization in cycles for Asian women.

In vitro fertilization with cryopreserved oocytes or embryos after cancer: The role of gestational carriers.

Fertility preservation counseling is recommended for reproductive-age cancer patients. Gestational carriers are individuals who carry a pregnancy for someone else. This service creates a path to biological children when cancer treatment necessitates the removal of the uterus. The authors examined the involvement of gestational carriers among women diagnosed with cancer. Using data from eight statewide cancer registries linked with the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System, the authors identified women with a cancer diagnosis who subsequently initiated in vitro fertilization (IVF) procedures during 2004 to 2018. Modified Poisson models were used to estimate prevalence ratios (PR) and 95% confidence intervals (CI). Discrete Cox regression models were used to calculate hazard ratios (HR) and CI. Multivariable models adjusted for age, state, and calendar year. Among 1095 women with cancer who used IVF with cryopreserved oocytes or embryos to attempt pregnancy, 19.1% worked with a gestational carrier. Involving gestational carriers was more common among those who initiated IVF for fertility preservation versus after cancer treatment (PR, 1.96; 95% CI, 1.54-2.50) and had chemotherapy versus no chemotherapy (PR, 1.92; 95% CI, 1.50-2.47). Using donor oocytes or embryos (vs. autologous) was more common among women who worked with a gestational carrier (PR, 1.62; 95% CI, 1.17-2.24). Working with a gestational carrier was not associated with conception (HR, 1.06; 95% CI, 0.82-1.37). Approximately one in five women diagnosed with cancer who used IVF to attempt pregnancy worked with a gestational carrier. The results of this study emphasize the need for information on gestational carriers during fertility preservation counseling.

Impact of race and ethnicity on in vitro fertilization outcomes in infertile women with polycystic ovary syndrome in the United States

Impact of race and ethnicity on in vitro fertilization outcomes in infertile women with polycystic ovary syndrome in the United States

Development of a novel calculator to predict gonadotropin dose and oocyte yield in oocyte cryopreservation cycles.

To develop a predictive model for estimating the total dose of gonadotropins and the number mature oocytes in planned oocyte cryopreservation cycles. In this retrospective study, oocyte cryopreservation cycles recorded in the Society for Assisted Reproductive Technology Clinic Outcome Reporting System Database from 2013 to 2018 were analyzed. Bivariate copula additive models for location, scale, and shape were performed to create a predictive model for estimating total dose of gonadotropins and number of mature oocytes. A total of 15,806 oocyte cryopreservation cycles between 2013 and 2018 were included in the analysis. The average age of participants was 35.4years, the mean duration of stimulation was 11.8days, and the average number of mature oocytes retrieved was 11.8. The treatment dose increased with age, FSH levels, BMI ≥ 35kg/m2, smoking, and history of diminished ovarian reserve, while it decreased with increasing AMH, ovulatory disorder, and BMI < 25kg/m2. The number of mature oocytes retrieved was positively correlated with AMH and negatively correlated with age, FSH levels, Asian race, and diminished ovarian reserve. With a maximum gonadotropin dosage of 450IU per day for 12 ± 3days of stimulation and a tolerance level of six mature oocytes, the predictive model achieved 70% accuracy. An interactive version of the equation was created as an online tool. We developed a predictive model to estimate the total treatment dosage and the number of mature oocytes. This calculator, utilizing objective patient variables, can assist in patient counseling prior to planned oocyte cryopreservation cycles.

Perinatal outcomes of women with recurrent pregnancy loss undergoing frozen embryo transfer from the Society of Assisted Reproductive Technology database

Perinatal outcomes of women with recurrent pregnancy loss undergoing frozen embryo transfer from the Society of Assisted Reproductive Technology database

Preimplantation genetic testing for aneuploidy is associated with reduced live birth rates in fresh but not frozen donor oocyte in vitro fertilization cycles: an analysis of 18,562 donor cycles reported to Society for Assisted Reproductive Technology Clinic Outcome Reporting System

Preimplantation genetic testing for aneuploidy is associated with reduced live birth rates in fresh but not frozen donor oocyte in vitro fertilization cycles: an analysis of 18,562 donor cycles reported to Society for Assisted Reproductive Technology Clinic Outcome Reporting System

Intracytoplasmic sperm injection versus conventional in vitro fertilization in unexplained infertility

Intracytoplasmic sperm injection versus conventional in vitro fertilization in unexplained infertility

Protocol change improves live birth and recurrent cycle cancellation rates after a previous IVF cycle cancellation: an analysis of 13000 autologous cycles reported to SART CORS.

After an IVF cycle cancellation, does changing the stimulation protocol affect the odds of live birth and recurrent cancellation in the subsequent cycle? After IVF cycle cancellation, compared to those who repeated the same stimulation protocol, those who changed their protocol had higher odds of live birth and lower odds of recurrent cycle cancellation. There is limited data addressing the effect of changing the stimulation protocol after an IVF cycle is cancelled during initial stimulation. The odds of live birth outcomes are not known so far in studies addressing the effect of changing the protocol. Retrospective Cohort Study using the 2014-2017 Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) database. The data included 13135 patients with a first autologous IVF cycle that resulted in a cycle cancellation and was followed by a second autologous cycle within the study period. We excluded fertility preservation cycles, supernumerary cycle attempts after the second IVF cycle attempt, and cycles with more than one stimulation protocol documented per cycle start. Patients who received the same protocol for both cycles (n = 6434) were compared to those who changed their protocol in the second cycle (n = 6701). Multivariable logistic regression analyses were performed to estimate the adjusted odds of live birth and recurrent cancellation. Changing the protocol in the second cycle resulted 14% lower odds of recurrent cycle cancellation (P = 0.01) and 17% higher odds of live birth after fresh transfers (P = 0.04). When stratifying the data by specific combinations of protocol change (agonist flare, agonist suppression, antagonist), there was an increase in live birth when switching from antagonist to agonist suppression (odds ratio (OR) = 1.36, P = 0.03) and from agonist suppression to antagonist (OR = 1.73, P = 0.01) compared to those who repeated their same stimulation protocol. Specifically in poor responders, outcomes were worse when using the agonist flare protocol and significantly improved with the agonist suppression protocol. Comparison of response to stimulation between first and second cycles cannot be made in this study because the index IVF cycle was cancelled during ovarian stimulation, and thus there is no reportable outcome data for that cycle. Additionally, SART only tracks the three stimulation protocols addressed in this study and does not have data on more contemporary protocols that are used in poor responders thus limiting the generalizability of our findings. Using the SART CORS database, which includes >90% of all reported IVF cycles in the USA, provides generalizability to the demographically diverse IVF populations found here. In agreement with prior studies assessing change in IVF protocols, the agonist flare protocol seems to result in worse IVF outcomes, and based on our results, we believe that there is no role for the agonist flare protocol in patients with a prior poor response to stimulation. None declared. N/A.

Gestational carrier cycles: embryology trends, national guideline compliance, and resultant perinatal outcomes in the United States, 2014–2020

Gestational carrier cycles: embryology trends, national guideline compliance, and resultant perinatal outcomes in the United States, 2014–2020

An investigation of racial and ethnic disparities in donor sperm availability in the United States

An investigation of racial and ethnic disparities in donor sperm availability in the United States

Assessment of a Decade of Change in U.S. Assisted Reproductive Technology Cumulative Live-Birth Rates: 2004-2009 Compared With 2014-2020.

To assess the effects of demographic shifts, changes in contemporaneous clinical practices, and technologic innovation on assisted reproductive technology (ART) success rates by conducting an analysis of cumulative live-birth rates across different time periods, age groups, and infertility diagnoses. We conducted a retrospective cohort study of autologous linked cycles comparing cumulative live-birth rates over successive cycles from patients undergoing their first retrieval between 2014 and 2019 in the SART CORS (Society for Assisted Reproductive Technology Clinic Outcome Reporting System) database. All cycles reported for these individuals up to 2020 were included for analysis. We compared cumulative live-birth rates stratified by age and infertility cause with published data from the 2004-2009 SART CORS database. From 2014 to 2019, 447,042 patients underwent their first autologous index retrieval, resulting in 1,007,374 cycles and 252,215 live births over the period of 2014 to 2020. In contrast, between 2004 and 2008, 246,740 patients underwent 471,208 cycles, resulting in 140,859 births by 2009. Noteworthy shifts in demographics were observed, with an increase in people of color seeking reproductive technology (57.9% vs 51.7%, P <.001). There was also an increase in patients with diminished ovarian reserve and ovulatory disorders and a decrease in endometriosis, tubal, and male factor infertility ( P <.001). Previously associated with decreased odds of live birth, frozen embryo transfer and preimplantation genetic testing showed increased odds in 2014-2020. Preimplantation genetic testing rose from 3.4% to 36.0% and was associated with a lower cumulative live-birth rate for those younger than age 35 years ( P <.001) but a higher cumulative live-birth rate for those aged 35 years or older ( P <.001). Comparing 2014-2020 with 2004-2009 shows that the overall cumulative live-birth rate improved for patients aged 35 years or older and for all infertility diagnoses except ovulatory disorders ( P <.001). This analysis provides insights into the changing landscape of ART treatments in the United States over the past two decades. The observed shifts in demographics, clinical practices, and technology highlight the dynamic nature of an evolving field of reproductive medicine. These findings may offer insight for clinicians to consider in counseling patients and to inform future research endeavors in the field of ART.

U.S. Gestational Carrier Embryo Transfer Trends, 2014–2020 [ID 2683526

INTRODUCTION: Multiple embryo transfers (METs) are common among gestational carriers (GCs) despite increased obstetric risks of multiple gestations and strong recommendations from American Society for Reproductive Medicine (ASRM) for single-embryo transfers. This study assessed GC embryo transfer trends from 2014–2020 to evaluate compliance with national guidelines. METHODS: This retrospective, population-based cohort study used data from the Society for Assisted Reproductive Technology Clinic Outcomes Reporting System. All cycles from 2014 to 2020 involving an embryo transfer to a GC were analyzed. The number of GC embryo transfers, use of preimplantation genetic testing (PGT), and outcome (singleton versus multiple gestation) were assessed. Poisson and linear regression models evaluated trends in number and proportion of cycles over time. Institutional review board approval was obtained. RESULTS: Of the 40,177 GC transfer cycles from 2014 to 2020, 11,081 (27.6%) involved transfer of two or more embryos. Both the number (n=2,001 in 2014; n=814 in 2020) and proportion of METs (56.6% of all transfers in 2014; 11.8% in 2020) (P&lt;.05 for both) decreased. The use of PGT among MET GC cycles increased from 23.9% in 2014 to 61.4% in 2020. Among live births, there was a 71.0% reduction in the proportion of multiple gestations from 2014 (25.5%) to 2020 (7.4%) (P&lt;.05). Among double-embryo transfers, the majority were performed at the blastocyst stage with an increase from 2014 (76.7%) to 2020 (88.1%) (P&lt;.05). CONCLUSION: With increased use of PGT and extended blastocyst culture, MET and subsequent multiple gestation pregnancies have decreased amongst U.S. GCs. These trends suggest increased compliance with ASRM national guidelines.

Psychosocial outcomes of children born via embryo donation.

What are parents' perceptions of their relationships with and the psychosocial adjustments of their children who are born via embryo donation? Families created through embryo donation have well-adjusted parent-child relationships and reassuring child psychosocial outcomes. Embryo donation is an effective and growing form of third-party reproduction, but there is limited research in this field. Prior studies suggest that families created through gamete donation function well regarding parent-child relationship quality and child behavioral and socioemotional adjustment. This is a cross-sectional survey study with 187 total participants. Parents of children born via embryo donation were recruited nationally by contacting all embryo donation programs registered with the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART CORS) as well as medically directed embryo donation or 'embryo adoption' centers. Participants completed three online Qualtrics questionnaires. The first was a survey including 33 questions on demographics, the procurement process, and self-reported obstetric outcomes. Participants also completed two standardized measures assessing children's behavior and parents' adjustment to parenthood: the Strengths and Difficulties Questionnaire (SDQ) and the Parental Acceptance-Rejection Questionnaire (PARQ). Scoring of the SDQ and PARQ was totaled and compared to standardized values (SDQ) or previously published results on other forms of gamete donation (PARQ), such as oocyte donation and sperm donation. On the SDQ (n = 46), the average total difficulties scores by age were: 8.2 ± 0.98 for ages 2-4, 7.6 ± 0.93 for ages 5-10, and 3.5 ± 0.77 for ages 11-17; this is compared to the normal reported range of 0-13, which indicates that clinically significant psychosocial problems are unlikely. Across all ages and individual categories (emotional symptoms, conduct problem, hyperactivity, peer problem, prosocial), scores on the SDQ were within the normal ranges. The average PARQ score (n = 70) for all respondents was 27.5 ± 1.18 (range: 24-96), suggesting perceived parental acceptance. Because this study was cross-sectional, it could not capture familial relationships over time. This survey-based study design allows for potential selection bias (parents of well-adjusted children may be more likely to participate). Additionally, the overall sample size is relatively small; however, it remains one of the largest published to date. Another significant limitation to this study is the lack of generalizability: most participants were recruited from private, faith-based, embryo donation programs who are demographically similar. Though embryo donation is an established form of third-party reproduction, it is significantly less robustly studied compared to other forms of gamete donation (oocyte or sperm donation). This study provides a larger data set with a more expanded age range of children compared to the limited number of previously published studies. Furthermore, these findings indicate a high parental disclosure rate with respect to the use of embryo donation which contrasts previous findings. No external funding source was utilized for the completion of this study. No conflicts are disclosed. N/A.

Similar pregnancy outcomes from fresh and frozen donor oocytes transferred to gestational carriers: a SART database analysis isolating the effects of oocyte vitrification.

This work aimed to study clinical and neonatal outcomes of embryos derived from frozen compared to fresh donor oocytes in gestational carrier cycles. This is a retrospective cohort study using the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database between 2014 and 2015, comprising of 1284 fresh transfer cycles to gestational carrier recipients of embryos resulting from fresh (n = 1119) and vitrified/thawed (n = 165) donor oocytes. Models were adjusted for gestational carrier age, preimplantation genetic testing (PGT-A), number of embryos transferred, multiple gestation, and fetal heart reduction. As our models were part of a larger analysis, intended parent BMI, smoking status, and parity were also adjusted for, but did not influence outcomes in this analysis. There was no significant difference in probability of live birth rates when comparing embryos derived from fresh and frozen donor oocytes in gestational carrier cycles. There were also no significant differences in biochemical pregnancy losses or clinical miscarriage. There were no significant differences noted in low birthweight or high birthweight infants derived from fresh versus frozen donor oocyte after transfer into a gestational carrier. The analysis of fresh and frozen donor oocytes in gestational carrier cycles provides the opportunity to assess for a possible effect of vitrification on the oocyte by controlling for differences in the uterine environment. We observed no significant differences in live birth, pregnancy loss, low birthweight or high birthweight infants when comparing fresh and frozen donor oocytes in gestational carrier cycles.

Higher live birth rates are associated with a normal body mass index in preimplantation genetic testing for aneuploidy frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System study

Higher live birth rates are associated with a normal body mass index in preimplantation genetic testing for aneuploidy frozen embryo transfer cycles: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System study

Frozen autologous and donor oocytes are associated with differences in clinical and neonatal outcomes compared with fresh oocytes: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System Analysis

Frozen autologous and donor oocytes are associated with differences in clinical and neonatal outcomes compared with fresh oocytes: a Society for Assisted Reproductive Technology Clinic Outcome Reporting System Analysis